Euroscreen opens US-IND for ESN364 on three Phase II trials

Gosselies, Belgium: 19 July 2016 - Euroscreen announced today that it has opened an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to conduct pivotal efficacy and safety assessments to evaluate ESN364 in Phase II studies for the treatment of menopausal Hot Flashes, Poly Cystic Ovary Syndrome and Uterine Fibroids.

More info on Euroscreen's website.

Next > FRX Polymers' Nofia® Flame Retardants Obtain Accreditation from Oeko-Tex® Association

Previous > Babette Pettersen joins Capricorn Venture Partners as Chief Business Development Officer